The Role of the Pharmacist in Unapproved Supply

Roughly 90% of medicinal cannabis products on the Australian market are unapproved therapeutic goods. That number surprises a lot of people. But it follows directly from how the Therapeutic Goods Act 1989 and the Poisons Standard are structured, and it puts pharmacists in an unusually active regulatory role , one that goes well beyond the counter transaction most people picture.

I've spent the last few years reading access pathway decisions and pharmacy board guidance so other people don't have to. This piece is my attempt to lay out, plainly, what the pharmacist's obligations actually are when an unapproved cannabis product moves through their dispensary.

Why most products are "unapproved" in the first place

The Australian Register of Therapeutic Goods (ARTG) is the national database of approved medicines. A product on the ARTG has satisfied the TGA's pre-market evaluation for quality, safety and efficacy. Most medicinal cannabis products , the oils, dried flower, capsules and the rest , are not on it. They've been manufactured to Good Manufacturing Practice standards, yes, but they haven't completed full ARTG registration.

That means every supply of those products to a patient requires a legal pathway to authorise unapproved use. There are two primary ones: the Special Access Scheme (SAS) and the Authorised Prescriber (AP) scheme. The SAS-B category, which covers most medicinal cannabis access, allows a registered medical or nurse practitioner to notify the TGA of their intention to prescribe without seeking individual approval each time. Authorised Prescribers have received TGA endorsement to prescribe a specific unapproved product to a class of patients without SAS notification per script.

Neither pathway removes the pharmacist from the picture. If anything, they move the pharmacist closer to the centre of it.

What "unapproved supply" means for the dispensary

Under the Therapeutic Goods Act 1989 (Cth), a pharmacist supplying an unapproved medicine is acting in reliance on the prescriber's SAS or AP authorisation. The pharmacist is not the authorising party; but they carry their own set of obligations.

These include verifying the prescription is valid and complete, checking that the prescriber holds the relevant state or territory authority to prescribe a controlled drug or prescription-only medicine, and ensuring the product dispensed actually matches what's on the script. Cannabis flower sits overwhelmingly at Schedule 8 under the Poisons Standard; CBD-only products below 150mg/day are Schedule 4. Each schedule carries different record-keeping, storage, and reporting requirements under the relevant state or territory Drugs and Poisons legislation, and those rules are not uniform across jurisdictions. A pharmacist in the ACT is working under different state-level rules than a colleague in Queensland, even for the same product.

I'll be honest: I've seen documentation from pharmacy inspections where the variance across jurisdictions catches dispensaries off guard. The federal framework looks tidy from the outside. The state-level overlay is where the complexity actually bites.

The pharmacist's role in verifying prescriber authority

This is the part of the pharmacist's function that doesn't get enough attention in general coverage of the access system.

Before dispensing, a pharmacist is expected to confirm the prescribing doctor has the appropriate authority. For an AP product, this means the prescriber should be able to demonstrate their TGA Authorised Prescriber status for that specific product and patient class. For SAS-B, notification to the TGA sits with the prescriber, but pharmacists may still request evidence that the notification has been lodged, particularly for Schedule 8 products, where pharmacist confidence in the chain of authorisation matters for their own regulatory exposure.

Several state pharmacy boards and the Pharmacy Board of Australia have published guidance noting that pharmacists retain professional and legal responsibility for each supply event. The supply is not made safe simply because a script exists. In practice, this means a well-run cannabis dispensary keeps records of prescriber authorisation status alongside the usual dispensing documentation.

Counselling obligations and the pharmacist's knowledge load

Here's something I reckon is underappreciated: a pharmacist dispensing an unapproved cannabis product is expected to counsel the patient in a clinically meaningful way, with effectively no approved Product Information document to work from.

Approved ARTG products come with a TGA-reviewed Product Information and Consumer Medicine Information sheet. Unapproved products don't carry that infrastructure. The pharmacist has the product's Certificate of Analysis, whatever the manufacturer has provided, and their own professional knowledge. That's it.

This requires a working understanding of how different cannabinoid compositions behave. A product high in THC carries different considerations than one that's predominantly CBD. Understanding the differences matters for counselling on onset, effect duration, and interactions; particularly with central nervous system depressants. Pharmacokinetics vary meaningfully depending on formulation and route; inhaled dried flower reaches systemic circulation rapidly, whereas an oil taken orally is subject to first-pass metabolism, which affects both timing and bioavailability.

In my view, the training burden being placed on community pharmacists here is significant, and the profession has had to build that knowledge base largely independently, without a formal TGA-approved educational scaffold. That's not a criticism of any individual pharmacist; most I've spoken to take it seriously. It's a structural gap in how the access regime was designed.

Real-time prescription monitoring and Schedule 8

For products at Schedule 8, which covers most THC-containing cannabis preparations; pharmacists in most Australian jurisdictions are required to check the relevant state real-time prescription monitoring (RTPM) system before dispensing. Systems like SafeScript in Victoria and ScriptCheckSA in South Australia are designed to flag potential high-risk prescribing patterns. Their implementation and integration into dispensing workflows varies by jurisdiction, but the obligation to check is real.

I was pulling up some notes on this while waiting for a long climb near Cooma on a Sunday ride last month, glamorous life, I know. The point is: a pharmacist missing an RTPM check for a Schedule 8 cannabis supply isn't just committing a technical breach. Depending on jurisdiction, it can be a disciplinary matter with serious professional consequences.

The compounding question

A smaller number of pharmacists operate as compounding pharmacies authorised to prepare cannabis preparations to a prescriber's specification. This is a distinct activity with its own regulatory overlay under TGA compounding guidance and state pharmacy legislation. Compounding pharmacies must hold appropriate licences and demonstrate that the compounded product is prepared under conditions consistent with pharmaceutical standards. The TGA has issued specific guidance on cannabis compounding that limits the practice to situations where no suitable approved or unapproved manufactured product exists.

Compounded cannabis is not a workaround. The TGA has been explicit that compounding cannot be used simply to provide a cheaper or more convenient alternative to an available manufactured product, a rule that matters as the market develops and more manufactured options come onto the ARTG or into the unapproved supply ecosystem.

Where the system relies on pharmacist diligence

The honest read of the Australian medicinal cannabis access architecture is that it distributes regulatory responsibility across prescribers, pharmacists, and the TGA; and relies heavily on each link performing its function. The TGA authorises (or accepts notification). The prescriber exercises clinical judgement and holds the primary authorisation. The pharmacist verifies, records, counsels, and supplies.

When it works, it functions. But the system's design means a failure at the pharmacy level, a missed RTPM check, a record-keeping gap, a supply made on a deficient script, doesn't just affect the individual patient. It creates a regulatory event that can trigger audits and compliance action from state pharmacy authorities, potentially affecting the whole dispensary's capacity to continue dispensing controlled substances.

Understanding the Schedule 8 framework, the SAS and AP pathways, and the state-level overlay isn't optional knowledge for a pharmacist in this space. It's the baseline.

Sources

• How to access unapproved therapeutic goods; TGA, Australian Government
• Guidance on the use of medicinal cannabis in Australia, TGA, Australian Government
• Controlled substances, Australian Government Department of Health and Aged Care
• Pharmacy Board of Australia; Regulatory guidance, AHPRA

, Marcus Hale, Regulatory researcher, TGA & access law